Coronary disease
Drug research and approvals for coronary disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 4,050 studies of coronary disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 4,050
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 1
- A Single-Center, Randomized Controlled Trial of Transcoronary Radiofrequency Ablation Versus Transcoronary Alcohol…NCT07950358 · Not applicable · Ligang Ding · starts Nov 16, 2026
- Prognostic Value of 2-Week ECG Monitoring After PCI in Acute Myocardial InfarctionNCT07947498 · Not applicable · Chungnam National University Hospital · starts Aug 2, 2024
- SGLT2 Inhibitor in Patients With Asymptomatic Moderate or Severe Aortic StenosisNCT07944066 · Phase 4 · Samsung Medical Center · starts Jun 10, 2026
- A Feasibility Study of a Wearable Arrhythmia Monitoring System (PulseON) in Stroke PatientsNCT07943065 · Not reported · University Hospitals Coventry and Warwickshire NHS Trust · starts Sep 16, 2026
- Multimodal Assessment of Remodeling and Stratification in Heart FailureNCT07940868 · Not reported · Shandong Provincial Hospital · starts Dec 1, 2022
- Effects of Primary Physician Presence in AI-Synthesized SGLT2 Inhibitor Educational Videos for Heart FailureNCT07937540 · Not applicable · Keimyung University Dongsan Medical Center · starts Aug 21, 2026
- Cardiopulmonary Exercise Active Health Cohort StudyNCT07935187 · Not reported · Peking University Third Hospital · starts May 11, 2026
- Implementing the 6th Generation Cardiac Troponin TNCT07936630 · Not applicable · Rasmus Bo Hasselbalch · starts Aug 1, 2026
- Prospective Cohort Study of Patients Undergoing Coronary Angiography in Vorarlberg, AustriaNCT07932327 · Not reported · Vorarlberg Institute for Vascular Investigation and Treatment · starts Mar 24, 2022
Approved 4
- SimvastatinHMG-CoA reductase inhibitor
- LovastatinHMG-CoA reductase inhibitor
- GemfibrozilPeroxisome proliferator-activated receptor alpha agonist
- PravastatinHMG-CoA reductase inhibitor
Phase 3 12 of 97
- ClopidogrelPurinergic receptor P2Y12 antagonist
- PrasugrelPurinergic receptor P2Y12 antagonist
- AtorvastatinHMG-CoA reductase inhibitor
- EzetimibeNiemann-Pick C1-like protein 1 inhibitor
- Estrogens, conjugatedEstrogen receptor agonist
- RosuvastatinHMG-CoA reductase inhibitor
- DalcetrapibCholesteryl ester transfer protein inhibitor
- HeparinAntithrombin-III activator
- ColchicineTubulin inhibitor
- XenonDiagnostic agent
- Insulin humanInsulin receptor agonist
- BivalirudinThrombin inhibitor
Phase 2 12 of 49
- Atuliflapon
- CangrelorPurinergic receptor P2Y12 antagonist
- AmilorideAmiloride-sensitive sodium channel, ENaC blocker
- AdenosineAdenosine receptor agonist
- PropofolGABA-A receptor; anion channel positive allosteric modulator
- Fospropofol
- AtopaxarProteinase-activated receptor 1 antagonist
- Varespladib methylPhospholipase A2 group IIA inhibitor
- UbidecarenoneSupplement
- Ammonia solution, strongDiagnostic agent
- MethotrexateDihydrofolate reductase inhibitor
- RiociguatSoluble guanylate cyclase positive allosteric modulator
Phase 1 or earlier 12 of 14
- VericiguatSoluble guanylate cyclase activator
- MoxifloxacinTopoisomerase IV inhibitor
- AcetylcholineMuscarinic acetylcholine receptor M3 agonist
- SildenafilPhosphodiesterase 5A inhibitor
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- PegfilgrastimGranulocyte colony stimulating factor receptor agonist
- RifampinBacterial DNA-directed RNA polymerase inhibitor
- PZ-128Proteinase-activated receptor 1 inhibitor
- ZalunfibanIntegrin alpha-IIb/beta-3 inhibitor
- Cocoa
- AmiodaroneHERG blocker
- BisoprololBeta-1 adrenergic receptor antagonist
How its trials ended
2,963 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 573 whose ending is known, 54% met their primary endpoint, 11% missed it and 35% stopped early.
- Completed, result not reported1,34745%
- Status unknown56119%
- Ongoing48216%
- Met its primary endpoint30710%
- Stopped: other or unclear1084%
- Missed its primary endpoint652%
- Stopped: enrollment or feasibility522%
- Stopped: sponsor or business decision201%
- Stopped: funding11<1%
- Stopped: lack of efficacy8<1%
- Stopped: safety2<1%
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Jul 24, 2026 | Colchicine Agepha PharmaColchicine | Agepha Pharma s.r.o. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA